Page last updated: 2024-11-04

flumequine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Flumequine is a synthetic antibacterial agent belonging to the fluoroquinolone class. It inhibits bacterial DNA gyrase, an enzyme essential for DNA replication, leading to bacterial cell death. Flumequine is primarily effective against gram-negative bacteria, including Salmonella, Escherichia coli, and Klebsiella pneumoniae. It is used to treat various infections, such as urinary tract infections, gastroenteritis, and respiratory infections. Flumequine is also used in veterinary medicine to treat infections in animals. However, its use has been restricted in some countries due to concerns about the development of bacterial resistance.'

flumequine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

flumequine : A racemate comprising equimolar amounts of R- and S-flumequine. A broad-spectrum antibiotic, formerly used in veterinary medicine for stock breeding and treatment of aquacultures. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid : A member of the class of pyridoquinolines that is 1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline carrying additional carboxy, methyl and fluoro substituents at positions 2, 5 and 9 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3374
CHEMBL ID370252
CHEBI ID85269
CHEBI ID94431
SCHEMBL ID49829
MeSH IDM0060382

Synonyms (137)

Synonym
MLS001074120
BRD-A69777949-001-05-1
42835-25-6
fluoro-methyl-oxo-[?]carboxylic acid
apurone
flumequine
1h,5h-benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-5-methyl-1-oxo
fantacin
KBIO1_000089
DIVK1C_000089
flumequinum [inn-latin]
imequyl
9-fluoro-6,7-dihydro-5-methyl-1-oxo-1h,5h-benzo(ij)quinolizine-2-carboxylic acid
6,7-dihydro-9-fluoro-5-methyl-1-oxo-1h,5h-quinolizine-2-carboxylic acid
r-802
flumigal
flumiquil
1h,5h-benzo(ij)quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-5-methyl-1-oxo-
flumix
r 802
flumisol
einecs 255-962-6
hsdb 7034
r 802 (bactericide)
flumequino [inn-spanish]
SPECTRUM_000367
PRESTWICK_603
BPBIO1_000207
NCGC00178300-01
NCGC00178300-02
BSPBIO_000187
IDI1_000089
SPECTRUM5_001532
PRESTWICK3_000204
BSPBIO_003094
FLM ,
apurone (tn)
flumequine (usan/inn)
D02302
PRESTWICK2_000204
NCGC00089803-03
NCGC00089803-02
smr000058826
MLS000069546 ,
KBIO3_002314
KBIO2_000847
KBIO2_005983
KBIOSS_000847
KBIOGR_001371
KBIO2_003415
SPECTRUM2_001200
SPECTRUM4_000826
SPBIO_002108
PRESTWICK0_000204
NINDS_000089
PRESTWICK1_000204
SPECTRUM3_001417
SPBIO_001279
SPECTRUM1500992
AC-1284
HMS2092O08
HMS500E11
nsc-757806
chebi:85269 ,
CHEMBL370252
HMS1568J09
HMS1921O10
NCGC00018211-03
NCGC00018211-04
NCGC00018211-02
NCGC00018211-06
NCGC00018211-05
HMS2095J09
pharmakon1600-01500992
nsc757806
tox21_110840
dtxcid3025623
dtxsid5045623 ,
F0832
9-fluoro-1,5,6,7-tetrahydro-5-methyl-1-oxopyrido[3,2,1-ij]quinoline-2-carboxylic acid
flumequino
flumequinum
9-fluoro-5-methyl-1-oxo-1,5,6,7-tetrahydropyrido[3,2,1-ij]quinoline-2-carboxylic acid
HMS2230F14
S3181
CCG-40315
uvg8vsp2sj ,
nsc 757806
unii-uvg8vsp2sj
flumequine [usan:inn:ban]
FT-0626439
AKOS015904879
HMS3373O15
flumequine [mi]
flumequine [ep monograph]
flumequine [usan]
flumequine [who-dd]
flumequine [inn]
flumequine [hsdb]
flumequine [mart.]
6,7-dihydro-9-fluoro-5-methyl-1-oxo-1h,5h-benzo(i,j)quinolizine-2-carboxylic acid
HY-B0526
6,7dihydro-9-fluoro-5-methyl-1-oxo-1h,5h-benzo[ij]-quinolizine-2-carboxylic acid
SCHEMBL49829
NCGC00018211-10
tox21_110840_1
HS-0096
Q-201123
9-fluoro-5-methyl-1-oxo-6,7-dihydro-1h,5h-pyrido[3,2,1-ij]quinoline-2-carboxylic acid
1h,5h-benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-5-methyl-1-oxo-
AB00052187_18
AB00052187_17
OPERA_ID_1399
mfcd00079298
DB08972
7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.0^{5,13}]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
sr-01000000130
SR-01000000130-2
CHEBI:94431
flumequine, vetranal(tm), analytical standard
flumequine, european pharmacopoeia (ep) reference standard
HMS3652K09
flumequine; (rs)-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1h,5h-benzo[i,j]quinolizine-2-carboxylic acid
SR-01000000130-4
SBI-0051623.P002
HMS3712J09
SW196774-3
Q3074500
BRD-A69777949-001-15-0
C75146
7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
A872809
flumequine 1000 microg/ml in acetonitrile
EN300-6482029
7-fluoro-12-methyl-4-oxo-1-azatricyclo[7.3.1.0,5,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
Z2065671185
SY052511

Research Excerpts

Overview

Flumequine is a broad-spectrum antimicrobial agent of the quinolone class. It is widely used as a veterinary drug in food-producing animals.

ExcerptReferenceRelevance
"Flumequine is a well-known second generation quinolone antibiotic that induces phototoxicity. "( Flumequine-Mediated Upregulation of p38 MAPK and JNK Results in Melanogenesis in B16F10 Cells and Zebrafish Larvae.
Choi, YH; Karunarathne, WAHM; Kim, GY; Kim, MS; Molagoda, IMN; Oren, M; Park, EK, 2019
)
3.4
"Flumequine is a quinolone derivative used in veterinary medicine to treat enteric infections, mainly those caused by Gram negative bacteria and also some Gram positive. "( Evaluation of the in vitro activity of flumequine against field isolates of Brachyspira hyodysenteriae.
Aller-Morán, LM; Carvajal, A; Martínez-Lobo, FJ; Rubio, P, 2015
)
2.13
"Flumequine is a broad-spectrum antimicrobial agent of the quinolone class, and it is widely used as a veterinary drug in food-producing animals. "( Degradation of flumequine by the Fenton and photo-Fenton processes: evaluation of residual antimicrobial activity.
Guimarães, JR; Maniero, MG; Rath, S; Rodrigues-Silva, C, 2013
)
2.19

Toxicity

ExcerptReferenceRelevance
" 100 mg l-1 are highly toxic and significantly decrease the growth of plants; this effect increases with time."( Phytotoxicity to and uptake of flumequine used in intensive aquaculture on the aquatic weed, Lythrum salicaria L.
Cozzolino, S; Fiori, M; Migliore, L, 2000
)
0.59
" These results demonstrate that in both photocatalytic processes studied, toxicity decreases significantly, producing a phototreated sample within safe toxicity limits."( Solar photocatalytic treatment of quinolones: intermediates and toxicity evaluation.
Agüera, A; Fernández-Alba, AR; Gernjak, W; Malato, S; Sirtori, C; Zapata, A, 2009
)
0.35
" An increase in toxicity was observed during chlorination suggesting that the first transformations products formed were more toxic than the parent compound."( Aqueous chlorination of levofloxacin: kinetic and mechanistic study, transformation product identification and toxicity.
Deborde, M; El Najjar, NH; Journel, R; Vel Leitner, NK, 2013
)
0.39
" In light of FLU's possible adverse effects on aquatic species, the removal of this antibiotic has received worldwide attention."( Fast removal of the antibiotic flumequine from aqueous solution by ozonation: Influencing factors, reaction pathways, and toxicity evaluation.
Feng, M; Sun, P; Wang, L; Wang, Z; Yan, L; Yang, S; Zhang, X, 2016
)
0.72

Pharmacokinetics

Flumequine had quite similar pharmacokinetic properties in halibut and turbot.

ExcerptReferenceRelevance
" The elimination half-life during PE (3."( Effect of plasma exchange on flumequine pharmacokinetics: comparison with control kinetics.
Dureux, JB; Gérard, A; Royer, RJ; Royer-Morrot, MJ; Schooneman, F; Zhiri, A, 1991
)
0.57
" The aims of this study were to examine and compare the pharmacokinetic properties of the quinolones oxolinic acid, flumequine, sarafloxacin, and enrofloxacin after intravascular and oral administration to Atlantic salmon (Salmo salar) by using identical experimental designs."( Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C.
Horsberg, TE; Martinsen, B, 1995
)
0.73
" No statistically significant differences were observed in the pharmacokinetic parameters of theophylline (volume of distribution, elimination half-life, AUC, plasma clearance) following the two treatments."( The quinolone, flumequine, has no effect on theophylline pharmacokinetics.
Audebert, C; Auquier, P; Blin, O; Durand, A; Horriere, F; Karsenty, H; Lacarelle, B, 1994
)
0.64
"The pharmacokinetic properties of flumequine and its metabolite 7-hydroxyflumequine were determined in six healthy sheep after single intramuscular (i."( Pharmacokinetics of flumequine in sheep after intravenous and intramuscular administration: bioavailability and tissue residue studies.
Chapel, AM; Delmas, JM; Gaudin, V; Sanders, P, 1997
)
0.9
" Pharmacokinetic modelling of the data showed that flumequine had quite similar pharmacokinetic properties in halibut and turbot."( Single-dose pharmacokinetics of flumequine in halibut (Hippoglossus hippoglossus) and turbot (Scophthalmus maximus).
Hansen, MK; Horsberg, TE, 1999
)
0.84
"Knowledge of the pharmacokinetic properties of drugs to combat bacterial infections in cod (Gadus morhua) and wrasse (Ctenolabrus rupestris) is limited."( Single-dose pharmacokinetics of flumequine in cod (Gadus morhua) and goldsinny wrasse (Ctenolabrus rupestris).
Hansen, MK; Horsberg, TE, 2000
)
0.59
"Knowledge of the pharmacokinetic properties of drugs to combat bacterial infections in the European eel (Anguilla anguilla) is limited."( Single-dose pharmacokinetics of flumequine in the eel (Anguilla anguilla) after intravascular, oral and bath administration.
Hansen, MK; Horsberg, TE, 2000
)
0.59
" The pharmacokinetic (PK) behavior of FLU administered to 32 healthy turkeys as an oral bolus via gavage or as 10-h pulsed administration in drinking water were compared, using the authorized dose of 15 mg/kg and the double dose of 30 mg/kg."( Pharmacokinetic/pharmacodynamic evaluation of the efficacy of flumequine in treating colibacillosis in turkeys.
Cagnardi, P; Ferraresi, C; Grilli, G; Intorre, L; Lucatello, L; Meucci, V; Montesissa, C; Piccirillo, A; Russo, E; Villa, R, 2013
)
0.63
"In this study, the pharmacokinetic profile of flumequine (FMQ) was investigated in blunt snout bream (Megalobrama amblycephala) after intravascular (3 mg/kg body weight (b."( Pharmacokinetics and bioavailability of flumequine in blunt snout bream (Megalobrama amblycephala) after intravascular and oral administrations.
Ai, X; Dong, J; Liu, Y; Xu, N; Yang, Q; Yang, Y, 2016
)
0.96

Bioavailability

The lack of colon bioavailability studies of flumequine in pigs makes it difficult to establish the true efficacy of this antibiotic for swine dysentery control. The absolute bioavailability of flumesquine after semisimultaneous intramuscular administration as a water-based suspension to veal calves was 92 +/- 14%.

ExcerptReferenceRelevance
"The oral absorption and bioavailability of flumequine was studied in 1-, 5- and 18-week-old calves following intravenous and oral administration of different formulations of flumequine (Flumix, Flumix C and pure flumequine)."( Oral absorption and bioavailability of flumequine in veal calves.
Breukink, HJ; de Grève, B; Guelen, PJ; Jansen, T; Mevius, DJ, 1989
)
0.81
" bioavailability of two injectable oily suspensions of the drug was 44%; both formulations failed to produce serum drug concentrations of potential clinical significance after administration at 20 mg/kg."( Clinical pharmacokinetics of flumequine in calves.
Bor, A; Kurtz, B; Soback, S; Ziv, G, 1986
)
0.56
" The bioavailability varied considerably among the four quinolones."( Comparative single-dose pharmacokinetics of four quinolones, oxolinic acid, flumequine, sarafloxacin, and enrofloxacin, in Atlantic salmon (Salmo salar) held in seawater at 10 degrees C.
Horsberg, TE; Martinsen, B, 1995
)
0.52
"The absolute bioavailability of flumequine after semisimultaneous intramuscular administration as a water-based suspension to veal calves was 92 +/- 14%."( Bioavailability of flumequine after semisimultaneous administration to veal calves.
Ceyssens, KG; de Grève, BI; de Jong, WT; Meijer, BA, 1994
)
0.9
" The bioavailability in halibut following a 2-h bath treatment was 5%."( Single-dose pharmacokinetics of flumequine in halibut (Hippoglossus hippoglossus) and turbot (Scophthalmus maximus).
Hansen, MK; Horsberg, TE, 1999
)
0.59
"The study demonstrates that the oral extent of bioavailability of flumequine in the rat, relative to the intravenous injection, is complete (0."( Pharmacokinetics, bioavailability and absorption of flumequine in the rat.
Bermejo, M; Freixas, J; Garrigues, TM; Merino, V; Ruiz-García, A; Sánchez-Castaño, G, 1999
)
0.79
" The oral bioavailability (F) was calculated to be 85%."( Single-dose pharmacokinetics of flumequine in the eel (Anguilla anguilla) after intravascular, oral and bath administration.
Hansen, MK; Horsberg, TE, 2000
)
0.59
"The pharmacokinetics and intramuscular (IM) bioavailability of flumequine (15 mgkg(-1)) were investigated in healthy pigs and the findings related to published minimal inhibitory concentrations (MICs) for susceptible bacteria of animal origin, and to experimentally determined MICs for susceptible strains of porcine origin."( Pharmacodynamics and pharmacokinetics of flumequine in pigs after single intravenous and intramuscular administration.
Acocella, F; Anfossi, P; Asta, F; Cagnardi, P; Carli, S; Massi, P; Villa, R, 2005
)
0.83
"5 h (Tmax) and bioavailability was about 93%."( Flumequine in the goat: pharmacokinetics after intravenous and intramuscular administration.
Cagnardi, P; Carli, S; Sonzogni, O; Villa, R, 2005
)
1.77
" Oral bioavailability was found to be 57%."( Oral bioavailability, tissue distribution and depletion of flumequine in the food producing animal, chicken for fattening.
Anadón, A; De La Cruz, C; Díaz, MJ; Martínez, M; Martínez, MA; Martínez-Larrañaga, MR, 2008
)
0.59
" The oral bioavailability (F) was 32."( Pharmacokinetics and bioavailability of flumequine in blunt snout bream (Megalobrama amblycephala) after intravascular and oral administrations.
Ai, X; Dong, J; Liu, Y; Xu, N; Yang, Q; Yang, Y, 2016
)
0.7
" The lack of colon bioavailability studies of flumequine in pigs makes it difficult to establish the true efficacy of this antibiotic for swine dysentery control."( Evaluation of the in vitro activity of flumequine against field isolates of Brachyspira hyodysenteriae.
Aller-Morán, LM; Carvajal, A; Martínez-Lobo, FJ; Rubio, P, 2015
)
0.94
" The results indicate that feed reduced the bioavailability of FLU from the gastrointestinal tract by at least 50% after the administration of a single oral dose."( Differences in the pharmacokinetics of flumequine after single and continuous oral administration in non-fasted broiler chickens.
Jaroszewski, JJ; Jasiecka-Mikołajczyk, A; Madej-Śmiechowska, H; Orzoł, A; Ziółkowski, H, 2018
)
0.75
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Flumequine administered at a dosage of 24 mg/kg bw every 24h for 5 days, with a withdrawal time of 2d ays, resulted in concentrations in target tissues that were less than the European Union maximal residue limits. Tetracycline, trimethoprim and an ineffective concentration of flumesquine given 48 h prior to sampling, strongly increased expression of plasmid mobility genes. An effective dosage of flomesquine resulted in lower levels of mRNA copies of these genes relative to placebo treatment.

ExcerptRelevanceReference
" After intramuscular injection of the same dosage rate of a 3% flumequine suspension is was best described by the one-compartment open model with first-order absorption."( Effects of experimentally induced Pasteurella haemolytica infection in dairy calves on the pharmacokinetics of flumequine.
Breukink, HJ; Jobse, AS; Kessels, BG; Mevius, DJ; Smit, JA; van Miert, AS, 1991
)
0.73
" and oral drug administration were used to calculate practical dosage recommendations."( Clinical pharmacokinetics of flumequine in calves.
Bor, A; Kurtz, B; Soback, S; Ziv, G, 1986
)
0.56
" The multiple dosage regimen yielded antimicrobial levels in both plasma and urine that were several-fold higher than the levels required to inhibit the growth of susceptible bacteria."( Plasma and urine levels of flumequine and 7-hydroxyflumequine following single and multiple oral dosing.
Funk, ML; Hansen, CS; Harrison, LI; Miller, HL; Ober, RE; Rohlfing, SR; Schuppan, D, 1985
)
0.57
"Simple assays for extraction and determination of the concentrations of the antibiotics oxytetracycline, oxolinic acid, and flumequine in a drug dosage form for farmed fish are described."( Extraction and analysis by high-performance liquid chromatography of antibiotics in a drug delivery system for farmed fish.
Rogstad, A; Weng, B, 1993
)
0.49
" Live catfish were dosed with 14C-labeled or unlabeled FLU to generate incurred residues."( Determination of flumequine in channel catfish by liquid chromatography with fluorescence detection.
Bencsath, FA; el Said, KR; Musser, SM; Plakas, SM; Walker, CC,
)
0.47
"47 microg/ml at intervals of 8 and 12 h, respectively) indicated that to maintain serum levels above MIC values for susceptible bacteria a dosage regimen of 20 mg/kg every 12 h is necessary by the intramuscular route."( Flumequine in the goat: pharmacokinetics after intravenous and intramuscular administration.
Cagnardi, P; Carli, S; Sonzogni, O; Villa, R, 2005
)
1.77
" Flumequine administered at a dosage of 24 mg/kg bw every 24h for 5 days, with a withdrawal time of 2d ays, resulted in flumequine concentrations in target tissues that were less than the European Union maximal residue limits."( Oral bioavailability, tissue distribution and depletion of flumequine in the food producing animal, chicken for fattening.
Anadón, A; De La Cruz, C; Díaz, MJ; Martínez, M; Martínez, MA; Martínez-Larrañaga, MR, 2008
)
1.5
" Tetracycline, trimethoprim and an ineffective concentration of flumequine given 48 h prior to sampling, strongly increased expression of plasmid mobility genes, whereas an effective dosage of flumequine resulted in lower levels of mRNA copies of these genes relative to placebo treatment."( Impact of antibiotic treatments on the expression of the R plasmid tra genes and on the host innate immune activity during pRAS1 bearing Aeromonas hydrophila infection in zebrafish (Danio rerio).
Cantas, L; Midtlyng, PJ; Sørum, H, 2012
)
0.62
" Based on these results, FLU administration should be adopted when specific diagnostic findings indicate its efficacy, and revising the dosage scheme to comply with the prudent and responsible use of antimicrobials in veterinary medicine is advisable."( Pharmacokinetic/pharmacodynamic evaluation of the efficacy of flumequine in treating colibacillosis in turkeys.
Cagnardi, P; Ferraresi, C; Grilli, G; Intorre, L; Lucatello, L; Meucci, V; Montesissa, C; Piccirillo, A; Russo, E; Villa, R, 2013
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
pyridoquinoline
3-oxo monocarboxylic acid
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Gluconeogenesis012

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency3.54810.044717.8581100.0000AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency25.05940.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency26.20000.177814.390939.8107AID2147
SMAD family member 2Homo sapiens (human)Potency30.10650.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency30.10650.173734.304761.8120AID1346859
TDP1 proteinHomo sapiens (human)Potency16.78890.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency33.49150.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency23.91450.000221.22318,912.5098AID743035
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.13140.000229.305416,493.5996AID743075
glucocerebrosidaseHomo sapiens (human)Potency31.62280.01268.156944.6684AID2101
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency56.23410.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency8.91250.035520.977089.1251AID504332
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.70790.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency36.12540.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency3.54810.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (131)

Assay IDTitleYearJournalArticle
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID572801Antimicrobial activity against soxS::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572818Antimicrobial activity against ramR-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID572810Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN18/21 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID572599Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN10055 harboring GyrA S83Y mutant gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572789Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium 543SA98 harboring GyrA S83Y mutant gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572788Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 543SA98 harboring plasmid encoded RamR gene, GyrA S83Y mutant gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572813Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN18/41 harboring plasmid encoded RamR gene, GyrA G81C,acrR mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572807Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN18 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID572792Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN9945 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572793Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN9181 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572802Antimicrobial activity against Salmonella enterica serovar Typhimurium S/921495 harboring plasmid encoded RamR gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID572791Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN9945 harboring plasmid encoded RamR gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID572796Antimicrobial activity against Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID406643Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/367-5043 isolate containing gyrA position 83 Ser-Ile substitution mutation from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID572787Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 543SA98 harboring GyrA S83F mutant gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572795Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN9181 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572794Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN9181 harboring plasmid encoded RamR gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID572804Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572597Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 102SA00 harboring plasmid encoded RamR gene, GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572600Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN10055 harboring plasmid encoded RamR gene, GyrA S83Y mutant gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572598Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium 102SA00 harboring GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID572816Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN18/71 harboring plasmid encoded RamR gene, GyrA G81C,acrR mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID572805Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572815Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/71 harboring plasmid encoded RamR gene, GyrA G81C,acrR mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572808Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/21 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572798Antimicrobial activity against marR-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID406640Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/363-5034 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID572817Antimicrobial activity against ramR::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572799Antimicrobial activity against marA::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID572593Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 902SA92 harboring GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID572797Antimicrobial activity against marR::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572596Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 102SA00 harboring GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID572803Antimicrobial activity against ramR-deficient Salmonella enterica serovar Typhimurium S/921495 harboring plasmid encoded RamR gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572811Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/41 harboring GyrA G81C,acrR mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID406641Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/422-5063 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID572786Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN10055 harboring GyrA S83Y mutant gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572814Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/71 harboring GyrA G81C, acrR mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID406644Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/494-5106 isolate containing parC position 83 Ser-Ile substitution mutation from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID572595Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium 902SA92 harboring GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572809Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/21 harboring plasmid encoded RamR gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572806Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18 harboring plasmid encoded RamR gene by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572594Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 902SA92 harboring plasmid encoded RamR gene, GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572812Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/41 harboring plasmid encoded RamR gene, GyrA G81C,acrR mutant genes by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID406639Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/363-5036 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID572800Antimicrobial activity against soxR::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID572790Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN9945 by agar doubling dilution method2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID406642Antimicrobial activity against Vibrio anguillarum serotype O2b 04/09/367-5042 isolate containing gyrA and parC quinolone resistance mutations from Atlantic cod at 30 ug by disc diffusion assay2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
gyrA and parC Mutations and associated quinolone resistance in Vibrio anguillarum serotype O2b strains isolated from farmed Atlantic cod (Gadus morhua) in Norway.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (206)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (16.02)18.7374
1990's37 (17.96)18.2507
2000's50 (24.27)29.6817
2010's71 (34.47)24.3611
2020's15 (7.28)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.79 (24.57)
Research Supply Index5.46 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index72.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (3.56%)5.53%
Reviews1 (0.44%)6.00%
Case Studies11 (4.89%)4.05%
Observational0 (0.00%)0.25%
Other205 (91.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]